Corteva, Inc. (CTVA) traded between $12.77 and $13.54 this week, climbing as much as 9% after JPMorgan raised its rating on the stock. Analyst Jeffrey Zekauskas moved shares to Buy from Hold on Tuesday and set a new price target of $19.

The new target sits far below the firm's previous $83 objective, but the drop is largely a mathematical artifact rather than a negative verdict on the business. Corteva completed a split into two separate companies on Oct. 1. The remaining Corteva retained the crop protection operations, while its seed technology arm—formerly DuPont's Pioneer unit—became an independent company named Vylor. Shareholders received one share of Vylor for every Corteva share they owned, meaning the combined value of their holdings was largely unchanged by the transaction.

Vylor opened for trading at $68.26 following the separation. Corteva's own share price fell 84% on Oct. 1, a decline that simply reflected the removal of the seed business from its valuation.

Trading activity in the days after the split underscored the adjustment period. New Corteva saw 88 million shares change hands on day one, followed by 79 million and then 183 million by day three. Vylor's volume was much lighter over the same stretch, at 15 million, 14 million, and 17 million shares, as investors worked out where each stock fits in their portfolios. Whether that turnover cools toward more ordinary levels is one early marker of how quickly the market settles on a shareholder base for each company.

What JPMorgan Sees in Corteva

Zekauskas values the crop chemicals business at roughly 10 times projected 2027 EBITDA, which works out to about $21 per share before accounting for legal risk. He reduced that figure to $19 to reflect potential PFAS and PFOA environmental liabilities—persistent, man-made chemicals whose cleanup and litigation costs have become an industry-wide issue for crop protection makers. JPMorgan estimates Corteva's share of those costs at approximately $1.3 billion, or $2 per share, assuming the total industry liability reaches $8 billion.

The new Corteva operates with a 38% gross margin and an EBITDA margin of 16.5% to 17%, while carrying close to zero net debt. JPMorgan puts the stock's EV/EBITDA multiple at 5.7 times for 2027, about a one-turn discount to rival FMC—a comparison that leans on FMC's status as the nearest listed pure-play peer for the newly standalone crop protection business.

Corn Prices and the Broader Backdrop

Benchmark corn prices are sitting near $5 per bushel, up 20% from a year earlier. Higher crop prices tend to benefit input suppliers such as Corteva, because farmers with stronger revenues have more cash available to spend on chemicals. That linkage now carries more weight than it did before Oct. 1: with the seed arm spun off, crop protection is Corteva's entire business rather than half of a diversified pair.

Zekauskas also flagged room for cost reductions, estimating that Corteva could trim $200 million a year from its cost structure. In addition, the company plans to license new crop chemical molecules from other industry players, an approach that could add growth without heavy research spending.

JPMorgan is not the only firm with a favorable stance. The average analyst price target for Corteva stands near $17, according to FactSet, about 35% above recent trading levels. While the firms differ on exact figures, their directional outlooks for the company line up. The spread between the targets largely comes down to how much weight each shop puts on crop protection headwinds versus Corteva's pipeline and cost levers.

Oppenheimer set its target at $17, down from $95 on a pre-split basis, while maintaining an Outperform rating. BMO Capital landed at $15, citing crop protection headwinds alongside the seed separation. Morgan Stanley went higher at $18, pointing to Corteva's research pipeline as a growth driver.

Mizuho kept an Outperform rating on Vylor specifically, with a $97 price target, noting that Vylor accounts for a large chunk of the old company's EBITDA. Oppenheimer also reiterated Outperform on Vylor, with a $95 target. For now, the post-split dust is still settling across both stocks, with the first quarters of standalone reporting, the path of corn prices, and any movement in PFAS liability estimates among the markers investors can watch as each business establishes its own record.

Source: CoinCentral